Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1971 1
1977 1
1982 1
1984 1
1985 1
1986 2
1987 1
1991 2
1992 1
1993 2
1994 1
1997 1
1999 2
2000 1
2001 1
2002 1
2003 2
2004 1
2005 4
2007 2
2008 4
2010 2
2011 1
2012 1
2013 5
2014 6
2015 3
2016 4
2017 3
2018 4
2019 2
2020 5
2021 3
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Page 1
Ewing sarcoma and Ewing-like tumors.
Sbaraglia M, Righi A, Gambarotti M, Dei Tos AP. Sbaraglia M, et al. Virchows Arch. 2020 Jan;476(1):109-119. doi: 10.1007/s00428-019-02720-8. Epub 2019 Dec 4. Virchows Arch. 2020. PMID: 31802230 Review.
Interestingly, despite significant morphologic overlap, most of these entities tend to exhibit morphologic features predictive of the underlying molecular alteration. Ewing sarcoma is the prototype of round cell sarcoma whereas in CIC sarcomas, focal pleomorphism and epith …
Interestingly, despite significant morphologic overlap, most of these entities tend to exhibit morphologic features predictive of the …
NKX3.1 immunoreactivity is not identified in mesenchymal chondrosarcoma: a 25-case cohort study.
Chen W, Hornick JL, Fletcher CDM. Chen W, et al. Histopathology. 2021 Jan;78(2):334-337. doi: 10.1111/his.14231. Epub 2020 Oct 19. Histopathology. 2021. PMID: 32779239
AIMS: Mesenchymal chondrosarcoma (MC) is characterised typically by a bimorphic microscopic appearance of islands of a well-differentiated cartilaginous component, admixed with a primitive small cell component, which commonly expresses CD99 and NKX2.2. ...Two differ …
AIMS: Mesenchymal chondrosarcoma (MC) is characterised typically by a bimorphic microscopic appearance of islands of a well-di …
Ewing Sarcoma and the History of Similar and Possibly Related Small Round Cell Tumors: From Whence Have We Come and Where are We Going?
Kilpatrick SE, Reith JD, Rubin B. Kilpatrick SE, et al. Adv Anat Pathol. 2018 Sep;25(5):314-326. doi: 10.1097/PAP.0000000000000203. Adv Anat Pathol. 2018. PMID: 29911999 Review.
Herein, we provide a comprehensive historical perspective on Ewing sarcoma, Ewing-like tumors (CIC and BCOR-rearranged sarcomas), and related and/or similar small round cell tumors, often included in the differential diagnosis, including mesenchymal chondrosarcoma, …
Herein, we provide a comprehensive historical perspective on Ewing sarcoma, Ewing-like tumors (CIC and BCOR-rearranged sarcomas), and relate …
The Differences Between Intracranial Mesenchymal Chondrosarcoma and Conventional Chondrosarcoma in Clinical Features and Outcomes.
Ma X, Meng G, Wang K, Li D, Wang L, Li H, Zhang J, Zhang L, Wu Z. Ma X, et al. World Neurosurg. 2019 Feb;122:e1078-e1082. doi: 10.1016/j.wneu.2018.10.230. Epub 2018 Nov 9. World Neurosurg. 2019. PMID: 30415056
OBJECTIVE: To report differences in clinical features and outcomes between intracranial mesenchymal chondrosarcoma (MCS) and conventional chondrosarcoma (CCS). ...Multivariate analysis revealed that tumor pathology and extent of surgery were independent predictor …
OBJECTIVE: To report differences in clinical features and outcomes between intracranial mesenchymal chondrosarcoma (MCS) and c …
Clinical Efficacy of Olaparib in IDH1/IDH2-Mutant Mesenchymal Sarcomas.
Eder JP, Doroshow DB, Do KT, Keedy VL, Sklar JS, Glazer P, Bindra R, Shapiro GI. Eder JP, et al. JCO Precis Oncol. 2021 Nov;5:466-472. doi: 10.1200/PO.20.00247. JCO Precis Oncol. 2021. PMID: 34994649 Free PMC article. Clinical Trial.
A patient with pulmonary epithelioid hemangioendothelioma had stable disease lasting 11 months. In contrast, clinical benefit was not observed among four patients with cholangiocarcinoma. CONCLUSION: These results indicate preliminary activity of PARP inhibition in patient …
A patient with pulmonary epithelioid hemangioendothelioma had stable disease lasting 11 months. In contrast, clinical benefit was not obs …
Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study.
Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, Gronchi A, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J. Frezza AM, et al. Eur J Cancer. 2015 Feb;51(3):374-81. doi: 10.1016/j.ejca.2014.11.007. Epub 2014 Dec 16. Eur J Cancer. 2015. PMID: 25529371 Free article.
BACKGROUND: Mesenchymal chondrosarcoma (MCS) is a distinct, very rare sarcoma with little evidence supporting treatment recommendations. ...Chemotherapy administration in patients with localised disease was associated with reduced risk of recurrence (P=0.046; hazard …
BACKGROUND: Mesenchymal chondrosarcoma (MCS) is a distinct, very rare sarcoma with little evidence supporting treatment recomm …
Repeated robotic pancreatectomy for recurrent pancreatic metastasis of mesenchymal chondrosarcoma: A case report.
Hayashida S, Ikenaga N, Nakata K, Nakamura S, Abe T, Ideno N, Endo M, Noguchi S, Oda Y, Nakamura M. Hayashida S, et al. Asian J Endosc Surg. 2023 Oct;16(4):795-799. doi: 10.1111/ases.13240. Epub 2023 Aug 13. Asian J Endosc Surg. 2023. PMID: 37574440
Mesenchymal chondrosarcoma is a rare subset of sarcomas accounting for 3%-10% of all cases of chondrosarcomas. ...Repeated pancreatectomy with minimally invasive techniques is a feasible and curative treatment for metastatic mesenchymal chondrosarcoma. …
Mesenchymal chondrosarcoma is a rare subset of sarcomas accounting for 3%-10% of all cases of chondrosarcomas. ...Repeated pan …
Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database.
Schneiderman BA, Kliethermes SA, Nystrom LM. Schneiderman BA, et al. Clin Orthop Relat Res. 2017 Mar;475(3):799-805. doi: 10.1007/s11999-016-4779-2. Clin Orthop Relat Res. 2017. PMID: 26975384 Free PMC article.
BACKGROUND: Studies suggest that mesenchymal chondrosarcoma is associated with a poorer prognosis and a higher proportion of extraskeletal tumors than conventional chondrosarcoma. ...QUESTIONS/PURPOSES: (1) What is the 5- and 10-year survival rate of patients diagno …
BACKGROUND: Studies suggest that mesenchymal chondrosarcoma is associated with a poorer prognosis and a higher proportion of e …
Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma.
Safaric Tepes P, Segovia D, Jevtic S, Ramirez D, Lyons SK, Sordella R. Safaric Tepes P, et al. Lab Invest. 2022 Sep;102(9):1038-1049. doi: 10.1038/s41374-021-00704-4. Epub 2021 Nov 26. Lab Invest. 2022. PMID: 34837064 Free article.
Mesenchymal chondrosarcoma (MCS) is a high-grade malignancy that represents 2-9% of chondrosarcomas and mostly affects children and young adults. ...In addition, patient-derived xenograft (PDX) models of MCS harboring the HEY1-NCoA2 fusion were developed from a prim …
Mesenchymal chondrosarcoma (MCS) is a high-grade malignancy that represents 2-9% of chondrosarcomas and mostly affects childre …
Advanced chondrosarcomas: role of chemotherapy and survival.
Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, Chaigneau L, Penel N, Duffaud F, Kurtz JE, Collard O, Bertucci F, Bompas E, Le Cesne A, Maki RG, Ray Coquard I, Blay JY. Italiano A, et al. Ann Oncol. 2013 Nov;24(11):2916-22. doi: 10.1093/annonc/mdt374. Epub 2013 Oct 7. Ann Oncol. 2013. PMID: 24099780 Free PMC article.
Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal chondrosarcoma, 20.5% for dedifferentiated chondrosarcoma, 11.5% for conventional chondrosarcoma and 0% for clear-cell chondrosarcoma ( …
Using RECIST, the objective response rate was significantly different according to histological subtype, being 31% for mesenchymal …
65 results